

T.C.  
SAĞLIK BAKANLIĞI  
Türkiye İlaç ve Tıbbi Cihaz Kurumu

Bu sertifika 28.12.2015 tarih ve 2015/955 sayılı ruhsatname eki olarak VEBULİS 10 MCG/ML NEBÜLİZATÖR İÇİN ÇÖZELTİ İÇEREN AMPUL isimli ilaç için düzenlenmiştir.

|                                              |                                                                                                            |
|----------------------------------------------|------------------------------------------------------------------------------------------------------------|
| REÇETELİ / REÇETESİZ                         | : REÇETELİ                                                                                                 |
| REÇETE TÜRÜ                                  | : BEYAZ                                                                                                    |
| RUHSAT SAHİBİ                                | : DEVA HOLDİNG A.Ş.                                                                                        |
| ETKİN MADDE ADI                              | : İLOPROST                                                                                                 |
| ÜRETİM YERİ                                  | : DEVA HOLDİNG A.Ş. KARTEPE/KOCAELİ                                                                        |
| PRİMER AMBALAJLAMA YERİ                      | : DEVA HOLDİNG A.Ş. KARTEPE/KOCAELİ                                                                        |
| SEKONDER AMBALAJLAMA YERİ                    | : DEVA HOLDİNG A.Ş. KARTEPE/KOCAELİ                                                                        |
| SERİ KONTROL ANALİZ YERİ İÇEREN              | : DEVA HOLDİNG A.Ş. KARTEPE/KOCAELİ                                                                        |
| SERİ SERBEST BIRAKMA YERİ                    |                                                                                                            |
| RAF ÖMRÜ(AY)                                 | : 24 AY                                                                                                    |
| SAKLAMA SICAKLIĞI (°C)                       | : 25°C'NİN ALTINDAKİ ODA SICAKLIĞINDA                                                                      |
| AMBALAJ TANIMI                               | : KUTUDA, PEMBE VE BEYAZ İKİ HALKA İLE KODLANMIŞ<br>2 ML ÇÖZELTİ İÇEREN 3 ML'LİK ŞEFFAF TİP I CAM<br>AMPUL |
| AMBALAJ BOYUTU                               | : 30 ADET                                                                                                  |
| BİLİMSEL İNCELEME SÜRESİNİN BAŞLANGIÇ TARİHİ | : 28.12.2015                                                                                               |
| RUHSAT HARCİ                                 | : 18.12.2015/98                                                                                            |
| ANALİZ HARCİ                                 | : 08.10.2014/2502565<br>08.10.2014/1                                                                       |

H.G.  
Dr. Hakkı GÜRSÖZ  
Kurum Başkan Yardımcısı



## ICH Press Release

Kobe, Japan, June 2018

### ICH continues membership expansion, and advances harmonisation work in electronic standards and pharmaceutical quality

Geneva, 22 June 2018

The International Council for Harmonisation (ICH) met in Kobe, Japan on 2 – 7 June 2018. In one of the remaining steps of implementing the 2015 reforms of ICH, the Assembly elected additional members to the Association's Management Committee. The Founding and Standing Members are now joined on the Management Committee by five newer ICH Members. CFDA, China, HSA, Singapore and MFDS, South Korea join the current regulatory members and BIO and IGBA join the current industry members.

Among other decisions, the ICH Assembly approved TFDA, Chinese Taipei as a new Regulatory Member. The Assembly also approved MMDA, Moldova, NPRA, Malaysia, SCDMTE, Armenia and TITCK, Turkey as new Observers. With these new parties, there are now 16 ICH Members and 27 Observers, and full details are available on the ICH website [www.ich.org](http://www.ich.org).

### ICH continues delivery across broad range of topics in drug development and maintenance

With the work of implementing the ICH reforms now largely completed, there was substantial progress at the Kobe meeting with the finalisation of 6 ICH harmonised guidance documents, as well as 2 draft guidance documents.

The following guidance documents were adopted by the Assembly at the Kobe meeting (*Step 4* of the ICH process):

- Revision of Q&As for the Electronic Submission of Individual Case Study Reports (E2B(R3));
- eCTD v3.2.2 Q&A and Specification Change Request Document v1.31 (M8);
- eCTD v4.0 Implementation Package v1.2 (M8);
- eCTD v4 Q&A and Specification Change Request Document v1.2 (M8);
- Specification for Submission Formats for CTD v1.2 (M8);
- Finally, it was noted that Q&As on Nonclinical Evaluation for Anticancer Pharmaceuticals (S9) were adopted through written procedure in April 2018.

The Assembly also noted the publication of revised recommendations on Electronic Transfer of Regulatory Information (ESTRI) (M2).


The following draft guidance documents were adopted for public consultation (*Step 2b* of the ICH process):

---

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

ICH Secretariat, Route de Pré-Bois 20, P.O. Box 1894, 1215 Geneva, Switzerland

Tel.: +41 (22) 710 74 80 - [admin@ich.org](mailto:admin@ich.org), <http://www.ich.org>



- Biopharmaceutics Classification System-based Biowaivers (M9);
- It was noted that the Guideline on Elemental Impurities: Revision to Cadmium inhalation Permitted Daily Exposures (Q3D(R1)) was endorsed through written procedure in May 2018.

#### **ICH prepares for future new topics**

The Assembly agreed to begin work on three new topics for ICH harmonisation:

- Analytical Procedure Development and Revision of Q2(R1) Analytical Validation (Q2(R2)/Q14);
- Continuous manufacturing (Q13);
- Clinical electronic Structured Harmonised Protocol ('CeSHarP') (M11).

Work will now begin on developing formal concept papers and work plans.

Two other new topics were also adopted with a delayed starting timeframe:

- Adaptive Clinical Trials;
- Drug interaction Studies.

The Assembly also discussed future strategic areas for harmonisation by endorsing a strategic reflection paper entitled Advancing Biopharmaceutical Quality Standards to Support Continual Improvement and Innovation in Manufacturing Technologies and Approaches.

#### **Training and stakeholder engagement to enhance implementation and adherence**

As the global impact of ICH grows, there is an increased focus on training and stakeholder outreach. The Assembly noted the development of training tools for regulators, industry and other stakeholders involved in drug development, to ensure consistent implementation and approaches to ICH guidelines. The training strategy will be delivered through trusted partners' programmes across the ICH regions, in addition to efforts of the ICH Expert Working Groups to develop their own training materials for guidelines.

In parallel, there are efforts to fully map the implementation of ICH guidelines by current and future ICH Members. Once completed, the outcome will be published on the ICH website so that all stakeholders can identify how ICH guidelines are implemented in their region.

The next ICH meeting takes place on 10-15 November 2018 in Charlotte, NC, USA.

\*\*\*\*\*

#### **NOTES FOR EDITORS**

This press release, together with more information on the Guidelines mentioned above and the work of ICH, can be found on its website: [www.ich.org](http://www.ich.org)

For further information, please contact the ICH Secretariat at [pressrelease@ich.org](mailto:pressrelease@ich.org)

Follow ICH on Twitter @ICH\_News

